Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

WuXi PharmaTech Begins Operation of New HPAPI Laboratory

Published: Thursday, May 29, 2014
Last Updated: Thursday, May 29, 2014
Bookmark and Share
Adds HPAPI processing capabilities at Shanghai lab.

WuXi PharmaTech (Cayman) Inc. has announced that its manufacturing subsidiary, Syn-The-All Pharmaceutical Co., Ltd. (STA), has begun operation of a high-potency active pharmaceutical ingredient (HPAPI) laboratory in Shanghai, thereby adding HPAPI processing to its portfolio of services.

The lab will support process development and clinical-trial supply of high-potency small molecules at kilogram scale.

"With the increasing use of HPAPIs in drug discovery and development, this new service augments WuXi's ability to provide highly efficient and cost-effective solutions for our partners worldwide," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

WuXi PharmaTech and PRA Health Sciences Restructure Relationship in China
Company will provide full-service clinical trial services for global clinical trials subcontracted by PRA in China.
Tuesday, December 15, 2015
WuXi PharmaTech and Lilly Announce Strategic Collaboration
Collaboration to develop, manufacture and commercialize a novel small molecule in China.
Saturday, November 14, 2015
WuXi, Lilly Announce Strategic Collaboration
WuXi PharmaTech and Eli Lilly have announced that they have entered into a strategic collaboration to develop, manufacture and commercialize a novel small molecule in China.
Thursday, November 12, 2015
WuXi PharmaTech Receives First Approval from Japanese Regulatory Authorities
STA subsidiary receives approval for the manufacture of the GMP intermediate of a branded commercial drug.
Thursday, September 03, 2015
WuXi PharmaTech and TruTag Complete Successful Testing of Authentication Solution
Covert, edible technology can be used to manage the pharmaceutical supply chain, prevent counterfeiting or diversion, and provide product informatics.
Thursday, August 20, 2015
WuXi and TruTag Complete Successful Testing of Edible On-Dose Authentication Solution for Pharmaceuticals
Covert, edible technology can be used to manage the pharmaceutical supply chain, prevent counterfeiting or diversion, and provide product informatics.
Wednesday, August 12, 2015
WuXi PharmaTech to Build New Cell Therapy Manufacturing Facility
Facility is designed for CAR T cells and other cancer immunotherapies.
Friday, March 20, 2015
WuXi Acquires NextCODE Health
NextCODE and WuXi's Genome Center will offer comprehensive clinical, research, and diagnostic testing products and services worldwide.
Monday, January 12, 2015
WuXi Opening Offices in Boston and San Francisco
New offices will give access to innovative companies in the world's two leading biotech hubs.
Friday, December 19, 2014
WuXi PharmaTech Laboratory Testing Division Expands in U.S.
XenoBiotic acquisition expands LTD’s presence in North America.
Wednesday, October 08, 2014
WuXi Facility Passes FDA API Manufacture Inspection
Company's wholly owned subsidiary Shanghai SynTheAll Pharmaceutical (STA) passed an FDA inspection in July for the manufacture of the active pharmaceutical ingredient (API) for a branded commercial drug.
Wednesday, August 20, 2014
WuXi PharmaTech Completes Construction of New Biosafety Testing Facility
Company announces that construction has been completed on a new biologics biosafety testing facility in Suzhou.
Tuesday, May 13, 2014
WuXi Breaks Ground on New Cell Therapy Manufacturing Facility
The facility in Philadelphia is expected to become operational in the second quarter of 2015.
Thursday, May 01, 2014
WuXi PharmaTech Announces Management Appointments
Dr. Steve Yang joins Company as EVP and chief operating officer and Edward Hu named chief investment officer and remains chief financial officer.
Thursday, April 17, 2014
WuXi and PRA Form Joint Venture
The agreement will offer a broad platform of Phase I-IV clinical trial services in China, Hong Kong and Macau.
Tuesday, January 01, 2013
Scientific News
The Rise of 3D Cell Culture and in vitro Model Systems for Drug Discovery and Toxicology
An overview of the current technology and the challenges and benefits over 2D cell culture models plus some of the latest advances relating to human health research.
World’s Largest Coral Gene Database
‘Genetic toolkit’ will help shed light on which species survive climate change.
A Boost for Regenerative Medicine
Growing tissues and organs in the lab for transplantation into patients could become easier after scientists discovered an effective way to produce three-dimensional networks of blood vessels, vital for tissue survival yet a current stumbling block in regenerative medicine.
Breast Cancer Drug Hope
A drug for breast cancer that is more effective than existing medicines may be a step closer thanks to new research.
Untangling Disease-Related Protein Misfolding
Work advances understanding of genetic forms of thrombosis, emphysema, cirrhosis of the liver, neurodegenerative diseases and inflammation, among others.
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Harnessing Nature’s Vast Array of Venoms for Drug Discovery
Scripps scientists have developed a method for rapidly identifying venoms.
Nanoparticles Target, Transform Fat Tissue
Nanoparticles designed to target white fat and convert it to calorie-burning brown fat slowed weight gain in obese mice without affecting food intake. This proof-of-concept work could lead to new therapies to treat obesity.
New Cancer Fighters Emerge From Lab
Rice University lab simplifies total synthesis of anti-cancer agent.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!